Skip to main content

Advertisement

Log in

Opinion statement

Nausea and vomiting are symptoms resulting from a triggered emetic reflex. Many endogenous and exogenous triggering factors can activate the emetic reflex, making understanding difficult and therapy challenging. The key to managing most cases of nausea and vomiting lies in a good history and a detailed physical examination. Most episodes of acute vomiting (lasting < 48 hours) have an evident triggering factor (eg, infection, viral illness, or food poisoning) and can be managed by removing the triggering agent and via supportive therapy. Chronic and unexplained nausea and vomiting can be a challenge. The cause is often obscure and requires special investigation. Functional gastroduodenal disorders such as cyclic vomiting syndrome, functional vomiting, and chronic idiopathic nausea should be considered if investigations are unrevealing. Knowledge regarding various emetic pathways and the specific neurotransmitters involved helps to target therapy. Histamine-1 receptor antagonists and muscarinic antagonists are suitable candidates for motion sickness and labyrinthine disorders. Phenothiazines, 5-hydroxytryptamine-3 receptor antagonists, corticosteroids, and benzodiazepines have a role in postchemotherapy and postoperative nausea and vomiting. Cannabinoid and neurokinin-1 receptor antagonists are best reserved for refractory cases of nausea and vomiting. Motilin agonists and metoclopramide are useful for treating impaired gastric motility disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Olden KW: Rumination. Curr Treat Options Gastroenterol 2001, 4:351–358.

    Article  PubMed  Google Scholar 

  2. Li BU, Misiewicz L: Cyclic vomiting syndrome: a brain-gut disorder. Gastroenterol Clin North Am 2003, 32:997–1019.

    Article  PubMed  CAS  Google Scholar 

  3. Talley NJ: Functional nausea and vomiting. Aust Fam Physician 2007, 36:694–697.

    PubMed  Google Scholar 

  4. Hornby PJ: Central neurocircuitry associated with emesis. Am J Med 2001, 111(Suppl 8A):106S–112S.

    Article  PubMed  Google Scholar 

  5. Quigley EM, Hasler WL, Parkman HP: AGA technical review on nausea and vomiting. Gastroenterology 2001, 120:263–286.

    PubMed  CAS  Google Scholar 

  6. Schwartzberg L: Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006, 4(2 Suppl 1):3–8.

    PubMed  CAS  Google Scholar 

  7. Glass PS, White PF: Practice guidelines for the management of postoperative nausea and vomiting: past, present, and future. Anesth Analg 2007, 105:1528–1529.

    Article  PubMed  Google Scholar 

  8. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130:1377–1390.

    Article  PubMed  Google Scholar 

  9. Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association: American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004, 127:1592–1622.

    Article  PubMed  Google Scholar 

  10. American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006, 24:2932–2947.

    Article  PubMed  CAS  Google Scholar 

  11. Flake ZA, Scalley RD, Bailey AG: Practical selection of antiemetics. Am Fam Physician 2004, 69:1169–1174.

    PubMed  Google Scholar 

  12. Golding JF, Stott JR: Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br J Clin Pharmacol 1997, 43:633–637.

    Article  PubMed  CAS  Google Scholar 

  13. McKeage K, Simpson D, Wagstaff AJ: Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. Drugs 2006, 66:2123–2147.

    Article  PubMed  CAS  Google Scholar 

  14. Cooper R, Gent P: An overview of chemotherapy-induced emesis highlighting the role of lorazepam as adjuvant therapy. Int J Palliat Nurs 2002, 8:331–335.

    PubMed  Google Scholar 

  15. Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007, 18:233–240.

    Article  PubMed  CAS  Google Scholar 

  16. Golembiewski J, Chernin E, Chopra T: Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm 2005, 62:1247–1260; quiz 1261–1262.

    Article  PubMed  CAS  Google Scholar 

  17. Sutton IR, Daeninck P: Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 2006, 4:531–535.

    PubMed  CAS  Google Scholar 

  18. Davis MP: Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 2008, 17:85–95.

    Article  PubMed  CAS  Google Scholar 

  19. Wilson EB, Bass CS, Abrameit W, et al.: Metoclopramide versus ondansetron in prophylaxis of nausea and vomiting for laparoscopic cholecystectomy. Am J Surg 2001, 181:138–141.

    Article  PubMed  CAS  Google Scholar 

  20. DiPalma JR: Metoclopramide: a dopamine receptor antagonist. Am Fam Physician 1990, 41:919–924.

    PubMed  CAS  Google Scholar 

  21. Tonini G, Vincenzi B, Santini D: New drugs for chemotherapy-induced nausea and vomiting: focus on palonosetron. Expert Opin Drug Metab Toxicol 2005, 1:143–149.

    Article  PubMed  CAS  Google Scholar 

  22. Navari RM: Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006, 2:591–602.

    Article  PubMed  CAS  Google Scholar 

  23. Maderazo EG: Diabetic gastroparesis. N Engl J Med 2007, 357:418–419; author reply 419–420.

    Article  PubMed  CAS  Google Scholar 

  24. Alvaro G, Di Fabio R: Neurokinin 1 receptor antagonists—current prospects. Curr Opin Drug Discov Devel 2007, 10:613–621.

    PubMed  CAS  Google Scholar 

  25. Milne RJ, Heel RC: Ondansetron. Therapeutic use as an antiemetic. Drugs 1991, 41:574–595.

    Article  PubMed  CAS  Google Scholar 

  26. Osorio-Sanchez JA, Karapetis C, Koczwara B: Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting. Intern Med J 2007, 37:247–250.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kevin W. Olden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chepyala, P., Olden, K.W. Nausea and vomiting. Curr Treat Options Gastro 11, 135–144 (2008). https://doi.org/10.1007/s11938-008-0026-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-008-0026-6

Keywords

Navigation